ArticleFrontiers in neuroscience2021
Neuroimage Biomarker Identification of the Conversion of Mild Cognitive Impairment to Alzheimer's Disease.
Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Resource-stratified machine learning framework for cognitive status classification and mild cognitive impairment to dementia progression prediction.Alzheimer's research & therapy · 2026Article
- Predicting Progression From Mild Cognitive Impairment to Alzheimer's Dementia With Adversarial Attacks.IEEE journal of biomedical and health informatics · 2024Article
- Machine learning with multimodal neuroimaging data to classify stages of Alzheimer's disease: a systematic review and meta-analysis.Cognitive neurodynamics · 2024Review
- Positive Effect of Super-Resolved Structural Magnetic Resonance Imaging for Mild Cognitive Impairment Detection.Brain sciences · 2024Article
- Effect of a novel telehealth device for dietary cognitive behavioral intervention in overweight or obesity care.Scientific reports · 2023Article
- Early detection of Alzheimer's disease using neuropsychological tests: a predict-diagnose approach using neural networks.Brain informatics · 2022Article
- Neuroimage Biomarker Identification of the Conversion of Mild Cognitive Impairment to Alzheimer's Disease.Frontiers in neuroscience · 2021Article
- Prediction and Modeling of Neuropsychological Scores in Alzheimer's Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks.Frontiers in computational neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An efficient method to identify whether mild cognitive impairment (MCI) has progressed to Alzheimer's disease (AD) will be beneficial to patient care. Previous studies have shown that magnetic resonance imaging (MRI) has enabled the assessment of AD progression based on imaging findings. The present work aimed to establish an algorithm based on three features, namely, volume, surface area, and surface curvature within the hippocampal subfields, to model variations, including atrophy and structural changes to the cortical surface. In this study, a new biomarker, the ratio of principal curvatures (RPC), was proposed to characterize the folding patterns of the cortical gyrus and sulcus. Along with volumes and surface areas, these morphological features associated with the hippocampal subfields were assessed in terms of their sensitivity to the changes in cognitive capacity by two different feature selection methods. Either the extracted features were statistically significantly different, or the features were selected through a random forest model. The identified subfields and their structural indices that are sensitive to the changes characteristic of the progression from MCI to AD were further assessed with a multilayer perceptron classifier to help facilitate the diagnosis. The accuracy of the classification based on the proposed method to distinguish whether a MCI patient enters the AD stage amounted to 79.95%, solely using the information from the features selected by a logical feature selection method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.